...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Drug-induced liver injury in 2007.
【24h】

Drug-induced liver injury in 2007.

机译：2007年药物性肝损伤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: To summarize the pertinent literature on the causes, epidemiology, prevalence, clinical features, evaluation and mechanisms of drug-induced liver injury reported during 2007. RECENT FINDINGS: Although the frequency of drug-induced liver injury remains low, new data from the Centers for Disease Control and Prevention confirm that of the approximately 1600 new acute liver failure cases annually, acetaminophen hepatotoxicity accounts for 41%; among children with acute liver failure, acetaminophen was the second most common cause. Antimicrobials lead the list of non-acetaminophen causes of drug-induced liver injury. In Asia, herbal compounds are the most common causes of the condition. Pravastatin was shown to be safe in patients with nonalcoholic fatty liver disease or chronic hepatitis C. The US Food and Drug Administration issued a draft guidance document on the premarketing clinical evaluation and stopping rules of drug-induced liver injury signals, including Hy's Law cases in clinical trials. SUMMARY: The year 2007 brought with it several reminders of the importance of drug-induced liver injury in the clinical trial as well as the clinical practice setting. There is additional evidence that statin drugs may be used safely in patients with chronic liver disease. Comments received by the US Food and Drug Administration to finalize their guidance document are eagerly awaited.
机译：审查目的：总结有关2007年期间报告的药物性肝损伤的原因，流行病学，患病率，临床特征，评价和机制的相关文献。最新发现：尽管药物性肝损伤的发生率仍然较低，但新数据疾病控制与预防中心的数据证实，每年约有1600例新的急性肝衰竭病例中，对乙酰氨基酚肝毒性占41％;在患有急性肝功能衰竭的儿童中，对乙酰氨基酚是第二常见的病因。抗菌药物在药物引起的肝损伤的非对乙酰氨基酚原因中排在首位。在亚洲，草药化合物是最常见的病因。普伐他汀被证明对非酒精性脂肪肝或慢性丙型肝炎患者是安全的。美国食品和药物管理局发布了一份指导文件草案，内容涉及上市前临床评估和停止药物引起的肝损伤信号的规则，包括Hy's Law病例。临床试验。简介：2007年带来了一些提醒，提醒人们在临床试验以及临床实践中药物性肝损伤的重要性。还有其他证据表明，他汀类药物可在患有慢性肝病的患者中安全使用。迫切希望获得美国食品和药物管理局（FDA）收到的有关最终确定其指导文件的意见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号